Pharma News
21 Sep 2025 to 27 Sep 2025
Sep 27, 2025
Vaiko Cautions Against Economic Conflict Over US Pharma Tariff, Calls for Special Parliamentary Meeting
MDMK leader Vaiko warned that the US's 100% import duty on pharmaceuticals could severely impact India's $12.7 billion pharma exports, primarily affecting generic drugs from companies like Dr. Reddy’s, Lupin, and Sun Pharma. He urged the Indian government to treat this as an economic emergency and convene a special Parliament session to address the crisis.
Sep 27, 2025
Trump Indicates Potential Effects on India with 100% Tariff on Pharmaceutical Imports Starting October 1
US President Donald Trump announced a 100% tariff on pharmaceutical imports starting October 1, 2025, which could significantly impact Indian drugmakers. The move aims to protect domestic industries but raises concerns about the availability and cost of pharmaceutical drugs in the US market.
Sep 27, 2025
Donald Trump's drug tariff excludes generic medications, yet India prepares for potential consequences.
President Trump announced a 100% tariff on branded and patented pharmaceutical imports starting October 1, 2025, unless companies build U.S. manufacturing plants. While generics, crucial to India's $20 billion export market, are exempt, concerns arise over potential disruptions to partnerships and supply chains. Major Indian exporters include Sun Pharma, Dr Reddy’s Laboratories, and Cipla. The move signals a shift towards domestic drug production.
Sep 27, 2025
Trump's tariffs: Who will be affected by the new pharmaceutical duties in the US? - The News Minute
Donald Trump announced a 100% tariff on branded and patented pharmaceutical imports starting October 1, 2025, unless companies build manufacturing plants in the US. Exemptions apply to generic drugs and firms with US production plans. Major companies like Eli Lilly, AstraZeneca, and Roche have pledged investments in US manufacturing. Experts warn this could raise costs for US consumers and disrupt supply chains.
Sep 27, 2025
Pharmacists Play a Key Role in Overseeing Drug Interactions for CDK4/6 Inhibitors in HER2-Positive Patients...
Pharmacists are crucial in managing drug interactions for patients receiving CDK4/6 inhibitors in HER2-positive breast cancer treatment. Their role includes monitoring adverse effects, ensuring proper dosing, and collaborating with healthcare teams to enhance patient care and treatment outcomes. This involvement aims to mitigate risks associated with these medications, improving overall management during therapy.
Sep 27, 2025
Trump imposes full 100% tariff on India's pharmaceutical exports of branded generics - Bhaskar English
India's pharmaceutical exports to the US, valued at $9.8 billion, are threatened by Trump's 100% tariff on branded drug imports, effective October 1. The ambiguity surrounding the definition of "branded" drugs, particularly branded generics, raises concerns for Indian suppliers. Despite zero tariffs, exports have declined by 13.3% from May to August 2025, highlighting the industry's challenges.
Sep 27, 2025
India Plans to Revise Drug Quality Regulations to Align with Standards of the US, EU, and Japan
India is set to revise its drug-quality regulations to align with US, EU, and Japan standards, aiming to enhance the safety and quality of its $50-billion pharmaceutical industry. This initiative is expected to strengthen India's global reputation in drug manufacturing and increase trust in its medical products.
Sep 27, 2025
CDSCO to overhaul CoPP submission procedure in response to delays faced by pharmaceutical companies in obtaining approvals.
The CDSCO is set to revamp the centralized e-filing process for Certificates of Pharmaceutical Product (CoPP) in response to drug exporters' concerns over approval delays. This restructuring aims to streamline the approval process and address the challenges faced by pharmaceutical companies in India.
Sep 27, 2025
Puducherry's Lieutenant Governor Kailashnathan Declares Action Against Counterfeit Medications
Puducherry Lt Governor K Kailashnathan announced a stringent crackdown on the sale of spurious drugs, emphasizing the serious risks they pose to public health. The administration aims to enhance safety measures and protect citizens from counterfeit medications.
Sep 26, 2025
Countries and companies at risk from Trump's pharmaceutical tariffs - Yahoo Finance
President Trump has announced a 100-percent tariff on all branded imported pharmaceuticals unless companies establish U.S. manufacturing plants by October 1. This move could impact major firms and drugs, including popular treatments like Wegovy and Mounjaro. The EU claims a prior trade deal protects its exports, while Switzerland's Roche, Novartis, and AstraZeneca face potential risks.
Sep 26, 2025
Trump's tariffs: Who will be affected by the new pharmaceutical duties in the US? - DW
President Trump announced a 100% tariff on branded and patented pharmaceutical imports starting October 1, 2025, unless companies build manufacturing plants in the US. This move could impact major firms like Eli Lilly, AstraZeneca, Roche Holding, and GSK, which have pledged significant investments in US production. Experts warn this may lead to higher costs and access issues for US consumers.
Sep 26, 2025
Trump's Full Tariffs Exclude Generic Medications and Pharmaceutical Shipments from Europe
Former President Donald Trump's announcement of 100% tariffs includes exemptions for generic drugs and European pharmaceutical exports, minimizing potential disruptions in drug availability and pricing. The policy also benefits companies relocating production to the U.S., reducing concerns over supply chain interruptions and increased costs for consumers and healthcare providers.
Sep 26, 2025
Trump reveals new tariffs on medications. What will your pharmacy bill look like?
President Trump announced a 100% tariff on brand-name drugs imported to the U.S. starting October 1, 2025, exempting companies building U.S. manufacturing plants. The tariffs will not apply to countries with existing trade deals, like Japan and EU nations. Experts warn this could lead to higher drug prices, complicating the already intricate U.S. drug pricing system.
Sep 26, 2025
Federal Circuit Rules That the Phrase 'Clinically Proven Effective' Does Not Confer Patentability
The Federal Circuit ruled that Bayer Pharma Aktiengesellschaft's patent claims for reducing cardiovascular events using rivaroxaban and aspirin were not patentable due to the term "clinically proven effective" being deemed non-limiting. Mylan Pharmaceuticals Inc. challenged the claims, asserting they were anticipated by prior art. The court emphasized that efficacy limitations must be specific to support patentability.
Sep 26, 2025
Will the Supreme Court Clarify Induced Infringement for Drug Manufacturers?
The Supreme Court may soon address the case of Amarin Pharma, Inc. v. Hikma Pharm. USA Inc., which involves the use of "skinny labels" by generic drug manufacturers to avoid patent infringement. The outcome could redefine labeling and marketing practices, impacting how generics like Vascepa® are marketed and potentially increasing scrutiny on their promotional statements.
Sep 26, 2025
Aquestive Shares Surge in After-Hours Trading as CEO Anticipates $1 Billion 'Blockbuster' Opportunity for Oral Allergy Treatment
Shares of Aquestive Therapeutics surged over 11% after CEO Dan Barber highlighted Anaphylm, an oral epinephrine film, as a potential "blockbuster" with peak sales of $1 billion. The FDA has set a target action date of January 31, 2026, for Anaphylm, which aims to replace traditional auto-injectors like EpiPen. Oppenheimer raised its price target for the company to $8.
Sep 26, 2025
Trump's warning on tariffs highlights advancements in US pharmaceutical manufacturing - Business Standard
President Trump's proposed 100% tariff on branded and patented drugs could significantly increase costs for pharmaceutical companies lacking US manufacturing. Firms like Novartis AG, Sanofi SA, Merck & Co., and Eli Lilly & Co. are expanding US operations to mitigate this risk. The tariff could impact around $220 billion in US pharmaceutical imports, raising average rates by 3.3 percentage points.
Sep 26, 2025
Bayer and Regeneron obtain exclusive market rights for Eylea following a patent ruling in Munich - JUVE Patent
Regeneron and Bayer are engaged in a global legal battle over their ophthalmic drug Eylea, facing several generic companies, including Formycon and Samsung Bioepis. Eylea, which generated $9 billion in sales in 2023, is crucial for both companies. The dispute centers on patent protections for aflibercept, with a key patent expiring soon, potentially allowing biosimilars to enter the market.
Sep 26, 2025
India grants approval to Ozempic: Novo Nordisk's popular diabetes medication receives endorsement from drug regulators.
The Central Drugs Standard Control Organization has approved Novo Nordisk's Ozempic (Semaglutide injection) for Type 2 Diabetes treatment in India. This GLP-1 receptor agonist enhances glycaemic control and offers cardiovascular and kidney benefits. With rising diabetes rates, Ozempic's launch strengthens Novo Nordisk's position in the market, complementing its existing products like Wegovy and Rybelsus.
Sep 26, 2025
Major Pharmaceutical Companies Are Set to Suffer Financial Losses Due to Expiring Patents - Jacobin
Major pharmaceutical companies are facing a patent cliff, with exclusive rights to key drugs like Merck's Keytruda expiring, potentially leading to a $236 billion revenue loss by 2030. In response, firms are opting for mergers, such as Merck's $10 billion acquisition of Verona Pharma, to secure new patents. This trend raises concerns over reduced innovation and increased drug prices.
Sep 26, 2025
Crinetics Gains FDA Approval for Uncommon Hormonal Disorder, Positioning It to Compete with Major Medications From...
Crinetics Pharmaceuticals has received FDA approval for Palsonify, a once-daily oral treatment for acromegaly, challenging established injectable therapies from Novartis and Ipsen. Palsonify, the company's first commercial product, showed significant efficacy in clinical trials. Priced at $290,000 annually, it aims to capture market share as patients seek alternatives to current treatments. A European submission is pending, with a decision expected in 2026.
Sep 26, 2025
NIH Funding Reductions Endanger Drug Development and Cancer Advances - WebProNews
Proposed budget cuts to the National Institutes of Health (NIH) could severely impact pharmaceutical innovation, as nearly 60% of new drug patents rely on NIH-funded research. Experts warn that a 20% reduction in NIH grants may delay drug approvals, affecting companies like Pfizer and Merck. The cuts threaten jobs and economic output, risking U.S. leadership in biomedicine.
Sep 26, 2025
Trump Proposes Full Tariff on Patented Medications in Latest Tariff Initiative - Bloomberg Law News
US President Donald Trump announced a 100% tariff on branded pharmaceuticals starting October 1, 2025, unless companies are building manufacturing plants in the US. Major drugmakers like Merck & Co., AstraZeneca, and Johnson & Johnson may be affected, as many rely on foreign production. The tariffs aim to boost domestic manufacturing amid ongoing trade tensions.
Sep 26, 2025
TWN urges that lenacapavir be offered generically to everyone for an annual cost of $40 - Pharmabiz.com
The Third World Network (TWN) has urged Gilead Sciences to make its HIV prevention drug lenacapavir available globally at $40 a year. While Gilead's recent agreements with generic manufacturers like Dr. Reddy’s Laboratories aim to expand access in 120 countries, TWN criticizes the exclusion of many nations and Gilead's restrictive licensing practices that hinder broader access.
Sep 26, 2025
Trump announces that the U.S. will implement a full 100% tariff on branded and patented medications unless companies establish manufacturing facilities domestically.
President Trump announced a 100% tariff on branded or patented pharmaceutical products entering the U.S. from October 1, exempting companies with ongoing manufacturing projects. This move aims to incentivize domestic production but has raised concerns among drugmakers like Eli Lilly and Johnson & Johnson about potential cost increases and supply chain disruptions. The tariffs follow a significant rise in U.S. pharmaceutical imports.
Sep 26, 2025
Hyderabad pharmaceutical firms proceed with caution following Trump's tariff declaration.
Hyderabad's pharmaceutical companies are cautiously navigating the landscape following Trump's tariff announcement. The industry sees this as a chance to enhance trade negotiations with other nations, diversify export markets, and increase investments in complex generics and biosimilars.
Sep 26, 2025
TN DCA dismantles significant illegal abortion pill operation, confiscates 6,720 MTP kits, according to DrugsControl Media Services.
The Tamil Nadu Drugs Control Administration has dismantled a major illegal abortion pill network, seizing 6,720 'Dr. Morepen MTP Kits' in a significant crackdown on unauthorized sales and distribution of abortion medicines.
Sep 26, 2025
Trump warns of a complete doubling of tariffs on pharmaceutical imports to the US.
In a two-part series, Mercedes Meyer from Banner Witcoff and Brandon Phemester of Novavax explore the underlying factors contributing to high medicine costs in the United States.
Sep 26, 2025
The Impact of Patents on Medicine Accessibility - Digestive Cancers Europe - Oncodaily
Digestive Cancers Europe will host a webinar on November 6 to discuss the impact of patents on medicine availability. Aimed at patient advocates, the session will provide insights and real-world examples to help participants navigate patent barriers and engage in discussions confidently. Registration is now open.
Sep 26, 2025
EU Declares Trump's Full 100% Tariff on Pharmaceuticals "Not Relevant" - Asia Economy
The European Union (EU) anticipates avoiding the 100% tariff on pharmaceuticals announced by U.S. President Donald Trump, as a joint statement limits tariffs on EU pharmaceuticals to 15%. Deputy Spokesperson Olof Gill emphasized that the EU is the only U.S. trading partner to secure this outcome, contingent on the U.S. implementing the agreement.
Sep 26, 2025
Study reveals possible effects of significant NIH budget reductions on upcoming drug development.
A new study co-authored by MIT researchers highlights the critical role of NIH funding in drug development, revealing that over 50% of FDA-approved small-molecule drugs since 2000, including Gleevec for chronic myeloid leukemia, cite NIH-backed research. The study warns that a proposed 40% budget cut to the NIH could jeopardize future medical advancements and the careers of promising scientists.
Sep 26, 2025
Countries and companies at risk from Trump's pharmaceutical tariffs - RFI
Donald Trump has announced a 100-percent tariff on all branded imported pharmaceuticals unless companies begin construction on U.S. manufacturing plants by October 1. This move could impact firms like Novartis and AstraZeneca, while generic drugs may be exempt. The EU claims a prior trade deal protects its exports, but uncertainty remains for other nations and companies.
Sep 26, 2025
The pharmacovigilance initiative for Ayush medications has seen an increase in the reporting of adverse drug reactions (ADRs) up to June.
The Pharmacovigilance programme for Ayurveda, Siddha, Unani, and Homoeopathy (ASU&H) drugs under the Ministry of Ayush reported 382 suspected Adverse Drug Reactions (ADRs) in the first half of 2025, marking a significant growth in ADR reporting. This figure represents nearly 73% of the total ADRs reported.
Sep 26, 2025
Countries and companies at risk due to Trump's pharmaceutical tariffs | FOX 28 Spokane
Donald Trump has announced a 100-percent tariff on all branded imported pharmaceuticals unless companies begin U.S. manufacturing by October 1. This move could impact firms like Novartis and AstraZeneca, while generic drugs are exempt. The EU claims a prior trade deal protects its exports, but countries like Switzerland and Denmark face potential risks.
Sep 25, 2025
What is AbbVie's Outlook for the Next Five Years? - AOL.com
AbbVie, the third-largest pharmaceutical company with a market cap of $390 billion, is expected to reduce its reliance on Humira while its successors, Skyrizi and Rinvoq, are projected to generate over $25 billion in sales this year. Despite potential challenges like tariffs and economic downturns, AbbVie is anticipated to maintain strong returns and grow its market cap to $600 billion by 2028.
Sep 25, 2025
AstraZeneca Shares Increase 15% Year-to-Date: Is It Time to Buy, Sell, or Hold? - TradingView
AstraZeneca (AZN) stock has surged 15% this year, outperforming the industry and S&P 500. Key drugs like Tagrisso, Lynparza, and Imfinzi drive revenue, while a strong oncology portfolio contributes significantly. However, challenges from Medicare Part D redesign and generic competition may impact sales. AstraZeneca aims for $80 billion in revenue by 2030, with a robust pipeline of new medicines.
Sep 25, 2025
AstraZeneca Shares Increase by 15% Year-to-Date: Is It Time to Buy, Sell, or Hold? - The Globe and Mail
AstraZeneca (AZN) stock has surged 15% this year, outperforming the industry and S&P 500. Key drugs like Tagrisso, Lynparza, and Imfinzi drive revenue, while a strong oncology portfolio contributes significantly. However, challenges from Medicare Part D redesign and generic competition may impact sales. AstraZeneca aims for $80 billion in revenue by 2030, with a robust pipeline of new medicines.
Sep 25, 2025
Eli Lilly Introduces New Weight-Loss Medication in India - The Straits Times
Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, offering a non-injectable alternative to GLP-1 drugs. The drug, which has shown promise in lowering blood sugar and weight, is set for regulatory approval in multiple countries. Eli Lilly's Mounjaro and Novo Nordisk's Wegovy have seen increased demand in the Indian market.
Sep 25, 2025
FDA Grants Priority Review for Daiichi's Enhertu sBLA for Breast Cancer - TradingView
AstraZeneca (AZN) and Daiichi Sankyo announced that the FDA has accepted a supplemental biologics license application for Enhertu, seeking label expansion for treating HER2-positive breast cancer. The filing, supported by positive phase III study results, has been granted priority review, with a decision expected in Q1 2026. Enhertu could set a new standard of care if approved.
Sep 25, 2025
Lilly halts phase 2 obesity study prior to beginning participant recruitment - Fierce Biotech
Eli Lilly has terminated a phase 2b obesity trial for bimagrumab, acquired in its $1.9 billion Versanis buyout, before patient enrollment, citing strategic business reasons. The study aimed to test bimagrumab alone and with tirzepatide, the active ingredient in Mounjaro and Zepbound. Lilly continues to study bimagrumab in an ongoing trial with tirzepatide, with results expected in 2026.
Sep 25, 2025
Bayer focuses on cell and gene therapies with an emphasis on Parkinson's disease | 104.1 WIKY
Bayer's experimental Parkinson's treatment, bemdaneprocel, developed by subsidiary BlueRock, has advanced to Phase III trials, marking a significant milestone in cell therapy. CEO Bill Anderson faces scrutiny as Bayer's pharmaceutical pipeline struggles post-patent expiries of Xarelto and Eylea. The company aims to address unmet needs in Parkinson's treatment, with the market projected to reach $7 billion by 2033.
Sep 25, 2025
What is AbbVie's Outlook for the Next Five Years? - The Globe and Mail
AbbVie, the third-largest pharmaceutical company with a market cap of $390 billion, is expected to reduce its reliance on Humira while its successors, Skyrizi and Rinvoq, are projected to generate over $25 billion in sales this year. Despite potential challenges like tariffs and economic downturns, AbbVie is anticipated to maintain strong returns and grow its market cap to $600 billion by 2028.
Sep 25, 2025
Key Highlights for Branded Pharmaceutical Stocks in Q2: Collegium Pharmaceutical (NASDAQ:COLL)
Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 revenues of $188 million, a 29.4% increase, exceeding expectations by 4.2%. The company focuses on abuse-deterrent opioid formulations and has seen its stock rise 18.3% post-results. Meanwhile, Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) also reported mixed results, with Supernus achieving a 25.5% stock increase.
Sep 25, 2025
Pharmaceutical Intermediate Market: Insights on Growth, Trends, and Future Projections for 2035
The pharmaceutical intermediate market is experiencing robust growth driven by rising chronic diseases and patent expiries for blockbuster drugs. Key players include Lonza, Catalent, and BASF. Trends such as outsourcing to CDMOs and a shift towards green chemistry are reshaping the landscape. North America remains a significant region, emphasizing supply chain resilience and regulatory compliance.
Sep 25, 2025
The Impact of Research Funding on the Advancement of Transformative Medications
A recent study highlights the critical role of National Institutes of Health (NIH) funding in the development of FDA-approved small-molecule drugs, including Gleevec for chronic myeloid leukemia. With proposed 40% budget cuts, over half of modern medications could be jeopardized, threatening future biomedical innovation and public health. The findings underscore the necessity of sustained NIH investment for ongoing drug discovery.
Sep 25, 2025
Effects of NIH Budget Reductions on Pharmaceutical Research and Innovation
A study by MIT and Johns Hopkins University reveals that over half of FDA-approved drugs from 2000 to 2023 are linked to NIH funding, which faces proposed cuts of 39.3%. The research highlights the potential negative impact of reduced NIH funding on drug development, emphasizing that many drugs rely on at-risk NIH grants for their discovery and innovation.
Sep 25, 2025
Research indicates that proposed budget reductions could significantly impact drug development negatively - Ars Technica
Proposed federal budget cuts could severely impact biomedical research, with a 40% reduction in funding for the National Institutes of Health (NIH). Researchers warn that such cuts could hinder the development of nearly half of newly approved drugs, as many rely on NIH-funded grants. Congress is currently considering maintaining existing funding levels for science agencies.
Sep 25, 2025
The impact of federal research funding on the development of transformative medications | MIT News
A new study co-authored by MIT researchers highlights the critical role of NIH funding in drug development, revealing that over 50% of FDA-approved small-molecule drugs since 2000, including Gleevec for chronic myeloid leukemia, cite NIH-backed research. The study warns that proposed 40% budget cuts to the NIH could jeopardize future medical advancements and the careers of promising scientists.
Sep 25, 2025
A different perspective on the NIH reveals that a 40% reduction in funding could hinder the development of new medications.
A study led by economist Pierre Azoulay highlights the detrimental effects of a proposed 40% cut to the NIH budget, suggesting it would have hindered the development of key drugs like Sanofi’s Cerdelga, Gilead’s Emtriva and Truvada, and Novartis’ Gleevec. The analysis warns that such cuts could jeopardize future medical innovations and the foundational research necessary for drug development.
Sep 25, 2025
Newron supports SPC for its Parkinson's medication Xadago in response to Purem - JUVE Patent
Newron Pharmaceuticals' safinamide, marketed as Xadago, is at the center of a legal dispute regarding its patent EP 2 474 521, which protects a high-purity form used for Parkinson’s treatment. The Munich Regional Court upheld a preliminary injunction against Purem, while the Federal Patent Court is set to review the patent's validity. Newron's SPC application for safinamide is also under appeal.
Sep 25, 2025
AstraZeneca Shares Increase by 15% Year-to-Date: Is It Time to Buy, Sell, or Hold? - sharewise
AstraZeneca (AZN) stock has surged 15% this year, outperforming the industry and S&P 500. Key drugs like Tagrisso, Lynparza, and Imfinzi drive revenue, while a strong oncology portfolio contributes significantly. However, challenges from Medicare Part D redesign and generic competition may impact sales. AstraZeneca aims for $80 billion in revenue by 2030, with a robust pipeline of new medicines.
Sep 24, 2025
What is Pfizer's Outlook for the Next Five Years? - The Globe and Mail
Pfizer's revenue surged past $100 billion in 2022 due to its COVID-19 products, Comirnaty and Paxlovid, but has since slowed as demand declines. Facing patent expirations on key drugs like Eliquis and Ibrance, Pfizer is focusing on new product launches and oncology, including its acquisition of Seagen, to drive future growth, aiming for $20 billion in revenue by 2030.
Sep 24, 2025
Many recently marketed medications are not truly 'new': Drug companies take advantage of patents to increase costs.
A 2023 study reveals that 78% of drugs linked to new patents are not genuinely innovative but rather minor modifications, a practice known as evergreening. This strategy prolongs market exclusivity and keeps drug prices high, raising concerns about patient access. Research indicates that disclosing clinical trial data during marketing authorization can deter low-value patent extensions, promoting genuine pharmaceutical innovation.
Sep 24, 2025
Hoth Files Patent for HT-001 Medication to Address Skin Reactions from Cancer Treatment - Stock Titan
Hoth Therapeutics, Inc. has expanded its intellectual property portfolio for HT-001, a topical treatment aimed at alleviating dermatological side effects associated with MENIN inhibitors, which are promising oncology drugs for acute leukemias and solid tumors. The new U.S. Provisional Patents cover conditions like drug-induced hypersensitivity and radiotherapy-induced rash, enhancing HT-001's therapeutic potential.
Sep 24, 2025
Hoth Therapeutics Broadens HT-001 Development Through New Patent Applications Aimed at Medication...
Hoth Therapeutics, Inc. has filed multiple U.S. Provisional Patents for HT-001, a topical treatment aimed at alleviating dermatological side effects associated with MENIN inhibitors used in oncology. The patents cover conditions like Drug-Induced Hypersensitivity Syndrome and Radiotherapy-Induced Rash, enhancing HT-001's potential in oncology supportive care. This move underscores Hoth's commitment to addressing significant unmet needs in cancer treatment.
Sep 24, 2025
Trump criticizes Ozempic, stating the medication has not made a significant impact on him - The Times of India
President Trump criticized the weight-loss drug Ozempic, labeling it the “fat pill” and questioning its effectiveness during a recent Oval Office briefing. His remarks followed a significant price cut for the drug in the U.S. Trump also reiterated unproven claims linking Tylenol to autism, aligning with his administration's efforts to challenge pharmaceutical companies.
Sep 24, 2025
Pharmaceutical companies embrace a 'more is better' strategy with their new wave of blockbuster antibodies.
The multi-specific antibody (msAb) category is gaining traction in pharma, with over 250 candidates in trials and 14 FDA-approved drugs, including Genentech’s Hemlibra and Vabysmo. Experts highlight potential in treating autoimmune diseases like lupus, leveraging T cell engagers for better outcomes. The market anticipates several msAb blockbusters by 2030, driven by innovative strategies and unmet medical needs.
Sep 24, 2025
Ozempic Tablet Proves Successful for Weight Loss - U.S. News & World Report
A clinical trial has shown that a daily pill of semaglutide, the active ingredient in Ozempic and Wegovy, can lead to nearly 14% weight loss in overweight individuals over 64 weeks, compared to 2% for a placebo. Novo Nordisk, the drug's manufacturer, anticipates FDA approval and aims to meet U.S. demand for this oral obesity treatment.
Sep 24, 2025
Is it Time to Move On from Pfizer and Invest in These Promising Stocks? - The Globe and Mail
Pfizer, with a 7.1% dividend yield, faces industry challenges and a high payout ratio, raising concerns after a past dividend cut. Competitors Bristol-Myers Squibb and Merck offer better dividend histories and lower payout ratios. Analysts suggest considering alternatives to Pfizer, as it wasn't included in a recent list of top investment stocks.
Sep 24, 2025
Ozempic Tablet Proves Successful for Weight Loss - FOX 28 Spokane
A clinical trial has shown that a daily semaglutide pill, the active ingredient in Ozempic and Wegovy, can lead to significant weight loss, with participants losing 14% to 17% of their body weight over 64 weeks. Novo Nordisk, the drug's maker, anticipates FDA approval for this oral treatment, which may increase access to obesity medications.
Sep 23, 2025
EMA panel suggests approval for STADA's biosimilar denosumab.
STADA Arzneimittel AG received positive recommendations from the EMA's CHMP for its biosimilars Kefdensis and Zvogra, targeting osteoporosis and advanced malignancies, respectively. These approvals would mark STADA's tenth specialty biosimilar, enhancing access to denosumab, a monoclonal antibody that reduces bone loss. The European denosumab market is valued at approximately €1 billion, with significant potential for patient access expansion.
Sep 23, 2025
Call for taxpayer support to provide weight-loss medications for 500,000 Australians - AFR
Novo Nordisk has requested the Australian federal government to subsidize its weight-loss drug Wegovy for 500,000 high-risk individuals with heart disease and obesity. The submission to the Pharmaceutical Benefits Advisory Committee aims to expand taxpayer funding for GLP-1 drugs, which also include Ozempic, beyond diabetes treatment.
Sep 23, 2025
Roche's goals in the obesity market are not dependent on a single major blockbuster drug - Fierce Biotech
Roche has unveiled its obesity strategy, aiming to become a top three player in the weight loss market. The company plans to launch the dual GLP-1/GIP receptor CT-388 by 2030, alongside other assets like CT-996 and petrelintide. Roche emphasizes a diverse portfolio to address obesity's complexities, while also exploring partnerships and potential acquisitions to enhance its pipeline.
Sep 23, 2025
Bristol Myers reports that its new blood cancer treatment meets objectives in important trial | BioPharma Dive
Bristol Myers Squibb's experimental drug iberdomide has shown promising results in a Phase 3 trial for multiple myeloma, surpassing standard treatment in eliminating disease signs. The study, Excaliber-RRMM, tested iberdomide with Darzalex and dexamethasone. While initial goals were met, further data on disease progression and survival are needed for regulatory approval.
Sep 23, 2025
Eli Lilly's Popular Weight-Loss Medications Propel $1.9 Billion in Trading Volume, Ranking 35th in Daily Transactions
Eli Lilly continues to lead the weight-loss drug market with products like Zepbound and Mounjaro, while also advancing its pipeline with orforglipron and retatrutide. Recent FDA approval of Kisunla (donanemab) for early-stage Alzheimer’s showcases its diversification. Eli Lilly's focus on innovation and scalability positions it for long-term growth in obesity and diabetes treatments.
Sep 23, 2025
Ipsen's LANTIC Phase II trial in aesthetics introduces a unique, long-lasting treatment option.
Ipsen announced promising Phase II trial results for its first-in-class molecule, IPN10200, designed for aesthetic treatments of glabellar lines. The data showed significant improvement in line severity at Week 4 and a longer duration of effect at Week 24 compared to placebo and Dysport. Phase III activities have begun, with results to be presented in H1 2026.
Sep 23, 2025
Youngkin vows to seek a negotiated solution for rising costs of weight loss medications.
Governor Glenn Youngkin vetoed a proposal to expand Medicaid access to weight loss drugs like Ozempic, citing concerns over cost-cutting negotiations with drug manufacturers. He promised a negotiated solution by December. Virginia's Medicaid spending on obesity and diabetes treatments is rising, with a projected 30% increase for diabetes in 2025. The legislature plans to revisit the access expansion in 2026.
Sep 23, 2025
Pfizer Makes Major Move with $7.3 Billion Acquisition of Metsera to Lead Weight Loss Sector
Pfizer Inc. announced a $7.3 billion acquisition of Metsera, a biotech firm specializing in obesity treatments, on September 22, 2025. This strategic move aims to enhance Pfizer's presence in the weight-loss market, currently dominated by Eli Lilly and Novo Nordisk. The deal, pending approvals, could significantly boost Pfizer's revenue amid declining COVID-19 vaccine sales.
Sep 23, 2025
Bausch and Teva face allegations of postponing the release of a generic form of the diarrhea medication Xifaxan - TradingView
Bausch Health and Teva Pharmaceuticals are facing a lawsuit for allegedly conspiring to delay the launch of a generic version of Bausch's diarrhea drug, Xifaxan, leading to inflated prices for consumers. The lawsuit claims Bausch paid Teva to postpone the generic's release until 2028, impacting healthcare costs significantly. Xifaxan generated nearly $2 billion in U.S. sales last year.
Sep 23, 2025
Innovent's obesity medication underscores the competitive landscape in China for Novo and Lilly - TradingView
Innovent Biologics has launched its weight-loss drug, Xinermei (mazdutide), in China, intensifying competition with Western rivals like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. Despite entering the market later, Innovent aims to raise awareness of weight management and has seen its shares rise 155% this year. Xinermei has also received approval for treating type 2 diabetes.
Sep 22, 2025
Which Pharmaceutical Stock Is Considered a Top Buy at the Moment? - The Globe and Mail
AbbVie, a leading pharmaceutical company, reported over $47 billion in net sales from 12 blockbuster drugs, including Skyrizi and Botox, in 2024. The company also boasts a strong dividend history, currently paying $1.64 per share. Despite competition, AbbVie remains a solid investment option due to its robust product lineup and consistent cash flow.
Sep 22, 2025
Growth Leaders: Eli Lilly's Weight Loss Boom Compared to Johnson & Johnson's Broad Strength
Eli Lilly (NYSE: LLY) is thriving with its focused strategy on GLP-1 drugs like Mounjaro and Zepbound, dominating the weight-loss and diabetes market. In contrast, Johnson & Johnson (NYSE: JNJ) maintains stability through a diversified approach across Innovative Medicine and MedTech. Both companies are shaping the pharmaceutical landscape, with Eli Lilly's growth driven by specialized innovation and J&J's resilience stemming from broad portfolio management.
Sep 22, 2025
Pancreatic Alpha Cells: Key Producers of GLP-1 in the Fight Against Diabetes
Researchers at Duke University have discovered that pancreatic alpha cells can produce bioactive GLP-1, a hormone crucial for insulin secretion and blood sugar regulation, challenging previous beliefs. This finding may lead to new treatments for type 2 diabetes, focusing on enhancing the body's natural GLP-1 production rather than relying solely on drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro).
Sep 22, 2025
Pharmaceutical Industry's $236 Billion Patent Scheme Is Poised for a Major Collapse - The Lever
Major pharmaceutical companies are approaching a significant patent expiration, potentially losing $236 billion in revenue by 2030 as exclusive rights for 190 high-earning drugs, including 69 blockbuster medications, expire. This "patent cliff" may lead to increased mergers in the industry, prioritizing consolidation over innovation, as generics and biosimilars enter the market, driving down drug prices.
Sep 22, 2025
FDA Approves Injectable Cancer Treatment Keytruda Qlex - Everyday Health
The FDA has approved an injected version of Keytruda (pembrolizumab), named Keytruda Qlex, for various solid tumors, offering a more convenient alternative to the intravenous form. The injection takes about two minutes compared to thirty for infusions, potentially reducing treatment time. Both forms show similar safety and effectiveness, according to Merck. Patient preference will guide the choice between the two.
Sep 22, 2025
Alvotech Submits PGR Challenge Against Regeneron's Patent for High-Dose Aflibercept - Mondaq
On September 17, 2025, Alvotech USA Inc. filed a Petition for Post Grant Review challenging the validity of Regeneron Pharmaceuticals' U.S. Patent No. 12,168,036, related to high-dose VEGF receptor fusion proteins for treating eye disorders. Alvotech argues the patent lacks novelty and written description, citing prior disclosures of aflibercept formulations. Regeneron's EYLEA HD® was FDA-approved in August 2023.
Sep 22, 2025
Calcutta High Court Overturns Refusal of Divisional Patent for Combination Drug
The Calcutta High Court has set aside the refusal of Pharmacyclics LLC's divisional patent application for a combination drug involving Ibrutinib and rituximab/ofatumumab. The court ruled that the application met the requirements of Section 16 of the Patents Act, emphasizing that divisional claims need not be limited to those in the parent application, as long as they are supported by the original specification.
Sep 22, 2025
Republicans Need to Take the Initiative Against Big Pharma's Patent Manipulations
A new white paper from the Association for Accessible Medicines highlights how Big Pharma exploits the Hatch-Waxman Act through serial patent litigation, delaying generic drug market entry and keeping prices high. The report calls for reforms to limit litigation tactics, ensuring fair competition and access to affordable medications for patients. Key lawmakers like Senators Mike Lee and Chuck Grassley are urged to lead these changes.
Sep 22, 2025
Korean Biotech Capitalizes on Leading Drug 'Keytruda'... Generates 1.6 Trillion Won Each Year
Alteogen's subcutaneous formulation of Keytruda has received FDA approval, marking a significant milestone for the Korean biotech firm. This technology is expected to generate over 1 trillion won in annual royalties. Keytruda, a leading cancer drug, offers faster administration options, enhancing patient convenience. Alteogen's success highlights the potential of Korean biotech on the global stage and paves the way for future innovations.
Sep 22, 2025
The Continued Presence of Inexpensive Imitations of Ozempic
The FDA's resolution of shortages for GLP-1 weight-loss drugs, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro), has led to ongoing sales of compounded versions by companies like Hims & Hers, despite legal warnings. Patients seek affordable alternatives, highlighting issues in the U.S. healthcare system regarding drug pricing and access.
Sep 22, 2025
Pfizer is close to finalizing a $7.3 billion deal to acquire Metsera, according to Financial Times - AInvest.
Pfizer is nearing a $7.3 billion acquisition of Metsera, a US weight-loss drug developer, to enter the anti-obesity market after its danuglipron drug failed trials. The deal, potentially announced Monday, includes $47.50 per share in cash and performance incentives. Metsera's GLP-1 therapy, MET-097i, showed promising results, positioning Pfizer against competitors like Eli Lilly and Novo Nordisk.
Sep 22, 2025
Roche's Ambitious Strategy: Targeting Dominance in the Obesity Medication Sector - Devdiscourse
Roche Holding's shares rose about 2% as the company announced its experimental obesity drug, CT-388, is entering late-stage clinical trials. Following its acquisition of Carmot Therapeutics, Roche aims to compete with major players like Novo Nordisk and Eli Lilly in the obesity drug market, targeting a top-three position by 2030.
Sep 22, 2025
[Market Update] Alteogen Rises More Than 10% Following U.S. Authorization of Cancer Treatment Injection... "Worldwide ...
Alteogen shares rose nearly 10% following FDA approval of Keytruda Qurex, an anticancer injection developed with Alteogen's recombinant human hyaluronidase alpha (ALT-B4). This innovation allows for quicker subcutaneous administration of immuno-oncology drugs. Analysts predict Alteogen could earn over 1 trillion won in annual royalties, marking a significant milestone for Korean biotechnology.
Sep 22, 2025
Research reveals that alpha cells generate GLP-1, similar to the effects of Ozempic medications - The Brighter Side of News
Researchers at Duke University have discovered that pancreatic alpha cells produce the hormone GLP-1, in addition to glucagon, challenging previous beliefs. This finding suggests GLP-1 plays a crucial role in insulin release and blood sugar regulation, potentially impacting diabetes treatments. The study highlights sex differences in GLP-1 secretion, which may lead to more personalized therapies. Results are published in Science Advances.
Sep 22, 2025
Eli Lilly's Rise: A Transformative Phase in Obesity Management Fueled by Zepbound and Orforglipron
Eli Lilly and Company (NYSE: LLY) reported a remarkable Q2 2025, with revenues soaring to $15.56 billion, driven by the success of its incretin-based drugs, Zepbound and Mounjaro. The company is expanding manufacturing to meet rising demand and plans to submit its oral GLP-1 agonist, orforglipron, for regulatory review in 2025, solidifying its leadership in the obesity treatment market.
Sep 21, 2025
Amgen Challenges Misleading Assertions from Academics Regarding Biologic Patents - IPWatchdog.com
Amgen has defended the current pharmaceutical patent system, asserting it fosters innovation that benefits patients. In response to misleading claims by the Initiative for Medicines, Access & Knowledge (I-MAK) regarding drugs like Lyrica®, Revlimid®, and Gleevec®, Amgen emphasizes the importance of accurate information in policy discussions, stating that the system is functioning effectively and supports ongoing advancements in biopharma.
Sep 21, 2025
Inexpensive Imitation Ozempic Was Expected to Disappear, Yet It Remains Ubiquitous. - Business Insider
The FDA's recent actions have led to a surge in compounded versions of weight-loss drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) despite legal ambiguities. Companies like Hims & Hers continue to sell these off-brand drugs, exploiting loopholes, while drugmakers Eli Lilly and Novo Nordisk face challenges in curbing this trend amid ongoing patient demand for affordable options.
Sep 21, 2025
Merck's Injectable Form of Popular Cancer Treatment Keytruda Receives FDA Green Light
The FDA has approved Merck's subcutaneous version of its cancer immunotherapy, Keytruda, now branded as Keytruda Qlex. This new formulation offers a less burdensome dosing option for patients and is indicated for 38 solid tumor types. Keytruda Qlex will be available in late September, following a successful Phase 3 study. Keytruda remains Merck's top revenue generator, with $15.1 billion in sales in the first half of 2024.
Sep 21, 2025
Your pancreas might be producing its own variant of Ozempic - ScienceDaily
A study from Duke University reveals that pancreatic alpha cells, previously known for producing glucagon, also generate GLP-1, a hormone that enhances insulin secretion and regulates blood sugar. This finding could reshape type 2 diabetes treatment by leveraging the body's natural GLP-1 production, similar to drugs like Ozempic and Mounjaro. The research highlights the flexibility of alpha cells in maintaining glucose balance.
Sep 21, 2025
Assessing AbbVie's (ABBV) Robustness in Maintaining Dividends During Challenging Periods
AbbVie (ABBV) maintains a 53-year streak of dividend increases, boasting a 3.07% yield. Despite a concerning payout ratio of 306.6% and declining earnings, strong cash flow from blockbuster drugs like Rinvoq, which generated $6 billion in 2024, supports its dividend. Strategic acquisitions and product diversification are crucial for sustaining this payout amid economic challenges.
Sep 21, 2025
A new era has started with the administration of anticancer medications in only one minute. This development follows...
Alteogen's partner Merck (MSD) has received FDA approval for the subcutaneous injection formulation of Keytruda, named Keytruda Curex, allowing administration in just one minute. This innovation, utilizing Alteogen's ALT-B4 technology, is expected to enhance patient convenience and aims to convert 30-40% of Keytruda doses to SC formulations within 18-24 months. European approval is also anticipated soon.
